Why oral semaglutide needs an absorption enhancer at all — one year on

Why oral semaglutide needs an absorption enhancer at all — one year on — that is the question, and I have not found it answered plainly anywhere I have looked.

Reading back through what has been written here about oral semaglutide, three questions come up every time and only one has ever been answered properly.

Listing all three, with what I think the state of the answer is for each, so the thread can start further along than the last one did.

Everything in the opening post holds. The case it does not cover is the one I have.

Anyone comparing published oral and injectable efficacy should check whether the comparison is within one trial or across two. Across two, the populations differ and the comparison is weak.

I would put this at better than even and not much better.

Oral semaglutide's bioavailability is low and variable, which is why the dose numbers are an order of magnitude different from the injectable. That is a formulation consequence and not a difference in potency.

SNAC is the sodium N-(8-[2-hydroxybenzoyl]amino) caprylate, an absorption enhancer that transiently raises local pH in the stomach and promotes gastric mucosal absorption. Without it, oral bioavailability of semaglutide would be too low for clinically useful dosing.

Post #4 answers the question as asked. The question underneath it is different.

Missed doses behave differently for a daily oral than for a weekly injection. With a short interval you are near a trough rather than perturbing a slowly moving average, and the labelling reflects that.

I have no interest in any supplier named above.

Good question, well framed, and I would like to see it answered properly.

PIONEER 6 was a cardiovascular safety trial for oral semaglutide, not an efficacy trial. Non-inferiority for safety was demonstrated. The point estimates favoured the drug but the trial was not designed to establish benefit.

Dose equivalence between oral and injectable formulations is not a simple conversion and no published factor should be used as one. The two were developed and titrated separately.

The general answer and the answer for your case may diverge here.

The practical argument for an oral is adherence, and the published adherence data is less flattering than the argument. Daily dosing with fasting requirements is not obviously easier than a weekly injection.

Orforglipron is a small molecule rather than a peptide, which changes almost everything about how it is made, stored and analysed. Comparing it to oral semaglutide as though they were the same pharmaceutical problem is a category error.

The thirty-minute wait before eating is not conservatism. Food in the stomach materially reduces absorption of the oral product, and the instruction exists because the pharmacokinetic studies measured how much.

If the premise is wrong, everything after it is decoration.

Taking post #9 at face value and following it one step further.

The class is broadening fast enough that anything written here about which orals exist is dated within a year. The mechanisms and the formulation constraints age much more slowly.

Why administration conditions matter for oral semaglutide and not for injectables: the oral formulation depends on a transient pH effect in the stomach. Anything that changes gastric pH or transit time changes absorption. Food does both.

I would call that likely rather than established.